drugset / Trial / NCT00150787

Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.

NCT00150787

Phase 3 Completed 250 enrolled UCB Pharma
RandomizedParallel-groupDouble-blind

Summary

A double-blind follow-up trial assessing the long term safety of Levetiracetam as per adverse events reporting, physical and neurological examination and vital signs

Timeline

Start
2003-07
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg Oral
Subject Levetiracetam Other / unclassified 3000 mg Oral